Nefiracetam CAS No.:77191-36-7 99.0% purity min. for nootropic

Product name:Nefiracetam
Other name:n-(2,6-dimethylphenyl)-2-oxo-1-pyrrolidineace , tamide;NEFIRACETAM;
2-oxo-1-pyrrolidinylacetica , cid,2,6-dimethylanilide;dm9384;
n-(2,6-dimethyl , phenyl)-2-oxo-1-pyrrolidineacetamid;DM-9384,(2-(2- , Oxopyrrolidin-1-
yl)-N-(2,6-dimethylphenyl)-ace , tamide);DMMPA
CAS No. 77191-36-7
Molecular formula:C14H18N2O2
Molecular weight:246.3
Purity:99.0%
Appearance:White powder
Packing :25 kg/barrel
Application:nootropic
3.Product introduction
Nefiracetam belongs to the non-borderline intelligence enhancing class of drugs,
which have different chemical structures and enhance cognitive ability and prevent
the damage of learning and memory through their effects on the cerebral cortex. It
does not have the properties of muscarinic receptor agonists and antagonists, nor
does inhibit the activity of Ach. The anti-forgetting and memory-enhancing effects
of this drug are achieved by enhancing the release of Ach in the cerebral cortex.
Camp-dependent protein kinases enhance Ca2+ channel activity, which may be
responsible for their enhanced Ach release. Nefiracetam (NEF) is a pyrrolidone type
nootropic agent with various pharmacologic as well as cognition enhancing effects.
In amygdala-kindled seizures, nefiracetam inhibits both electroencephalographic and
behavioral seizures. NEF has a distinct anticonvulsant spectrum.
4.Feature
Nefiracetam is used to treat cerebrovascular diseases. It can enhance the cognitive
ability and prevent the damage of learning and memory by its effect on the cerebral
cortex. It does not have the properties of muscarinic receptor agonist and
antagonistic agent, nor does it inhibit the activity of acetyl cholinase .
Therefore, its anti-forgetting and memory-enhancing effects occur by improving the
release of acetylcholine in the cerebral cortex.
5.Applications
Nefiracetam is a hydrophobic derivative of piracetam and a synthetic synthesis of
all Racetam compounds piracetam. Nefiracetam is manufactured primarily by Daiichi
Sankyo (Japanese pharmaceutical company) for the treatment of AD. In addition to
all the mechanisms attributed to Nefiracetam， it is generally thought to be a
substance that is responsible for the discovery of calcium channels in the body, as
well as the indirect transfer of the excitation signaling substance, acting as a
partial agonist of the glycine-binding site of the NDMA receptor.

Minimum Order: 1 bags

Click to Enlarge